Cite
HARVARD Citation
Wang, F. et al. (2019). One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial. Journal of ophthalmology. p. . [Online].